300 rectal cancer Patients' tissues analyzed to unlock secrets of treatment response
NCT ID NCT07499921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will look at tumor samples and health records from 300 people who had surgery for rectal cancer. The goal is to find patterns in the tumor's immune environment that can predict which patients will respond well to chemotherapy or immunotherapy. This could help doctors identify patients who might avoid surgery and preserve their rectum, improving quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Léon Bérard
Lyon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?